Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 7/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 7/20 | 0.34 |
| ▸ | RELA | Q04206 | 7/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7110632 | 0.82 | CHRM3 (0.40) | DRD2DRD3ALDH1A1HTR1AHTR1D | |
| SCHEMBL7110625 | 0.82 | CHRM3 (0.40) | DRD2DRD3ALDH1A1HTR1AHTR1D | |
| SCHEMBL14092141 | 0.81 | L3MBTL1 (0.35) | L3MBTL1NFKB1NFKB2RELACA2 | |
| SCHEMBL14046826 | 0.78 | L3MBTL1 (0.36) | L3MBTL1NFKB1NFKB2RELATDP1 | |
| SCHEMBL6626738 | 0.77 | KDM4E (0.48) | DRD2DRD3DRD4KDM4EALDH1A1 | |
| SCHEMBL7114723 | 0.77 | KDM4E (0.48) | DRD2DRD3DRD4KDM4EALDH1A1 | |
| SCHEMBL7202944 | 0.75 | MLNR (0.35) | DRD2DRD3HTR1A | |
| SCHEMBL12377772 | 0.74 | L3MBTL1 (0.39) | L3MBTL1NFKB1NFKB2RELATDP1 | |
| SCHEMBL7114678 | 0.74 | KDM4E (0.38) | L3MBTL1NFKB1NFKB2RELATDP1 | |
| SCHEMBL18505012 | 0.74 | L3MBTL1 (0.39) | L3MBTL1NFKB1NFKB2RELATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258602-B2 | Macrocyclic ghrelin receptor modulators and methods of using the same | OCERA THERAPEUTICS, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-9949949-B2 | Macrocyclic ghrelin receptor modulators and methods of using the same | OCERA THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9949949-B2 | Macrocyclic ghrelin receptor modulators and methods of using the same | OCERA THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170042858-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY | 2017-02-16 | — | — | US | disclosed |
| US-20170042858-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY | 2017-02-16 | — | — | US | disclosed |
| EP-2118080-B1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | OCERA THERAPEUTICS INC (US) | 2016-08-31 | — | — | EP | disclosed |
| US-9371297-B2 | Macrocyclic ghrelin receptor modulators and methods of using the same | OCERA THERAPEUTICS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9371297-B2 | Macrocyclic ghrelin receptor modulators and methods of using the same | OCERA THERAPEUTICS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| WO-2008130464-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | TRANZYME PHARMA, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | TRANZYME PHARMA INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | TRANZYME PHARMA INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258602-B2 | Macrocyclic ghrelin receptor modulators and methods of using the same | GHSR, GHRHR, GIPR | L3MBTL1 1333/4885NFKB1 3330/4885NFKB2 3306/4885 |
| US-20170042858-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | GHSR, GHRHR, GIPR | L3MBTL1 1328/4885NFKB1 3414/4885NFKB2 3423/4885 |
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | GHSR, GHRHR, GIPR | L3MBTL1 1333/4885NFKB1 3330/4885NFKB2 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.